|
|
| 2025 BioPlan's 22nd Annual Survey--Biopharmaceutical Manufacturing | For over 20 years, we continue to be the leader in providing the biopharma industry's most comprehensive benchmarking analysis. We invite you to participate in our 22nd Annual Survey in Biopharmaceutical Manufacturing! For all completed, qualified responses, we'll send an Amazon egift card, a copy of the summary results (mid-2025), and our 2025 Top Trends in Biomanufacturing White Paper. |
|
|
|
|
By AR Welch, Editorial & Community Director, Advancing RNA | As I took stock of the year behind us, there were five overarching ways in which I saw our industry taking steps forward and finding itself on sturdier scientific and clinical footing. Here, in the second of this two-part article, I continue down this list with my last three takeaways. | |
|
|
|
By S. Chowdhury, et.al., Lifescience Dynamics | As we enter 2025, RNA therapeutics are poised to command significant attention from industry leaders as well as emerging players. | |
|
|
|
It goes without saying that achieving cell-specific delivery is the most often discussed challenge facing the RNA-LNP field near- and long-term. However, as these three LNP experts share in this Advancing RNA Live clip, they have a whole list of additional R&D and CMC priorities we must address/accomplish to improve RNA-LNPs’ efficacy in personalized and gene therapy approaches. |
|
|
|
By Kishore Hotha, Dr. Hotha’s Life Sciences LLC | Oligonucleotides and peptides require precise, scalable, and compliant production. CDMOs are integrating AI-driven technologies to answer the call. Many of these technologies are notable for specific needs. | |
|
|
|
|
| Optimized And Scalable LNP Composition For RNA Vaccine Delivery | Poster | By Natalie Orr, Mikayla Walsh, Cayden Yu, Victoria Hartman, et al., Cytiva | Explore results from a study screening novel LNP formulations for physicochemical attributes, in vitro potency, and in vivo immunogenicity in both SARS-CoV-2 and influenza vaccine applications. |
|
|
| Manufacturing Strategies For mRNA Vaccines And Therapeutics | White Paper | By Laurens Vergauwen, Dr. Nargisse El Hajjami, Mag. Manuel Brantner, et al., MilliporeSigma | mRNA has emerged as a promising modality offering a great deal of versatility for a wide range of therapeutics and vaccines with its use of non-viral delivery systems. |
|
|
|
| Future Proof Your Process Scale Workflow | Infographic | Cytiva | Our goal is the same as yours: to fight disease, one new biologic at a time. Discover how to future-proof your process scale workflow, from starting bases to tangential flow filtration. |
|
|
|
|
.png){kind=logo}
